Cargando…
INHIBITION OF PACLITAXEL AGAINST NEUROGLIOMA CELLS U251 GROWTH AND ITS MECHANISM
BACKGROUND: Glioma is the most common primary tumor of the central nervous system, and accounted for about 70% of primary tumors. MATERIALS AND METHODS: In the study, antitumour activity and mechanism of paclitaxel was investigated. Different concentrations of paclitaxel (200, 300, 400 μmol/L) was t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
African Traditional Herbal Medicine Supporters Initiative (ATHMSI)
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411869/ https://www.ncbi.nlm.nih.gov/pubmed/28480395 http://dx.doi.org/10.21010/ajtcam.v14i1.19 |
Sumario: | BACKGROUND: Glioma is the most common primary tumor of the central nervous system, and accounted for about 70% of primary tumors. MATERIALS AND METHODS: In the study, antitumour activity and mechanism of paclitaxel was investigated. Different concentrations of paclitaxel (200, 300, 400 μmol/L) was treated in neuroglioma cellsU251. RESULTS: Paclitaxel significantly inhibited neuroglioma cells growth, and promoted its apoptosis. Paclitaxel can block tumour cells in the G2/M phase. In addition, apoptosis-related genes caspase-3 and bax expressions were increased after paclitaxel treatment. CONCLUSION: Our work indicated that paclitaxel displayed strong anti-tumour activity. |
---|